Anthropic CEO Dario Amodei published a 3,800-word essay arguing that the mounting risks of AI warranted a slowdown. In as ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results